1994 Study Found Cannabis Use Improved Infant Outcomes. No One Followed Up.

A peer-reviewed study published three decades ago found that Jamaican infants exposed to cannabis in utero performed better on developmental assessments than unexposed peers. The research has been largely ignored by the medical establishment ever since.

"The babies with the most cannabis exposure did the best," said Melanie Dreher, the study's lead researcher, in a recent interview. "Either nobody read it, or nobody wanted to touch it."

The 1994 study examined infants born to women in rural Jamaica, where cannabis use during pregnancy was culturally accepted and relatively common. Dreher's team conducted neurobehavioral assessments at three days and one month of age, comparing exposed and unexposed infants while controlling for other variables.

The results contradicted prevailing assumptions about prenatal cannabis exposure. Yet the study generated neither the controversy nor the follow-up research Dreher anticipated. No major replication studies emerged. No additional funding materialized to expand the work.

The Research Gap

Today, pregnant women in the United States face criminal prosecution and child protective services investigations for cannabis use in multiple states. The American College of Obstetricians and Gynecologists recommends against cannabis during pregnancy, citing potential developmental risks.

But the evidence base remains thin. Most studies on prenatal cannabis exposure rely on self-reported use data and don't control adequately for confounding factors like tobacco use, alcohol consumption, or socioeconomic status. The Jamaican research, conducted in a population where cannabis use wasn't stigmatized and women reported honestly, offered rare methodological advantages.

Dreher's findings haven't been definitively disproven—they've simply been sidelined. Medical organizations continue to issue blanket warnings based largely on animal studies and correlation-based human research that can't establish causation.

Legal and Social Consequences

The gap between scientific uncertainty and policy certainty has real consequences. Women in at least 24 states can face criminal charges or lose custody of their children if they test positive for cannabis during pregnancy or childbirth, according to data from the Guttmacher Institute.

These prosecutions have accelerated as legal cannabis markets expand. Some hospitals in legal states still report positive cannabis tests to child welfare authorities, even when no other risk factors are present. Women of color face disproportionate testing and reporting rates, mirroring broader disparities in drug enforcement.

Meanwhile, the cannabis industry has grown into a $30 billion market with minimal research into pregnancy-related questions. Federal restrictions on cannabis research have prevented large-scale studies that might clarify risks or confirm safety in specific contexts.

What Comes Next

Some researchers are revisiting questions about prenatal cannabis exposure as legalization spreads and self-reported use during pregnancy increases. The National Institutes of Health's Adolescent Brain Cognitive Development Study is tracking children exposed to cannabis in utero, though results won't be conclusive for years.

Dreher's work remains one of the few prospective studies conducted in a non-stigmatized setting. Whether modern researchers will attempt to replicate her findings—or whether funding agencies will support such politically fraught research—remains uncertain.

For now, pregnant women continue to navigate contradictory information: cultural traditions suggesting cannabis is safe, medical establishments warning against any use, and a scientific literature that's remarkably incomplete given how common the question is.

---

This article is based on original reporting by hightimes.com.